表紙
市場調查報告書
商品編碼
974802

尼曼匹克症C型治療的市場規模:各疾病類型、年齡層、地區 - 佔有率,預測,機會分析(2020年∼2027年)

Niemann-Pick Disease Type C Treatment Market by Disease Type, By Age Group, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日期: | 出版商: Coherent Market Insights | 英文 144 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球尼曼匹克症C型(NPC)治療市場,市場參與企業為了將產品投入市場獲得法規當局認證的努力,推動成長。

企業,致力於研究和開發,以確定可能在未來開發新療法的疾病目標,開始臨床試驗以鑑定參與導致疾病進展的途徑的新型蛋白質。該蛋白也可用於早期診斷,可以針對NPC的治療方案的開發,預計將推動市場成長。

本報告提供全球尼曼匹克症C型(NPC)治療市場的相關調查,市場機會和趨勢,開發和新產品的認證/銷售,成長及阻礙因素,各疾病類型、年齡層、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各疾病類型
    • 市場明細:各年齡層
    • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 法規方案
  • 主要的開發
  • 市場趨勢
  • 合併和收購方案
  • 新產品的認證/銷售
  • PEST分析

第4章 Covid-19大流行的影響

  • COVID-19流行病學
  • COVID-19對臨床實驗的影響
  • 為了對抗COVID-19的政府舉措

第5章 市場分析:各疾病類型(2016-2027)

  • 簡介
  • 尼曼匹克症C第一型
  • 尼曼匹克症C2型

第6章 市場分析:各年齡層(2016-2027)

  • 簡介
  • 嬰兒
  • 兒童
  • 成人

第7章 市場分析:各地區(2016-2027)

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Orphazyme ApS
    • CTD Holdings Inc
    • Neurotrope Inc
    • Okklo Life Sciences BV
    • Intrabio Ltd
    • Azafaros
    • Centogene AG Rostock
    • Actelion Pharmaceuticals Ltd
    • Mallinckrodt Pharmaceuticals
    • Merck & Co., Inc.,
    • Alexion Pharmaceuticals
    • Sanofi Genzyme
    • Aldagen Inc.
  • 分析師的見解

第9章 Section

目錄

Title:
Niemann-Pick Disease Type C Treatment Market, by Disease Type (Niemann-Pick Diseases Type C1 And Niemann-Pick Diseases Type C2), By Age Group (Infantile, Juvenile, and Adult), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Niemann-Pick disease type C (NPC) is a rare genetic disorder that is a type of lysosomal storage disorder. NPC leads to accumulation of cholesterol and other fatty substances in different tissues of the body, such as brain and others. The onset of specific symptoms for NPC varies from person to person. In most cases, the symptoms appear in the childhood, which progresses to cause life-threatening complications with increasing age. NPC occurs as a result of mutations in the NPC 1 gene and NPC 2 gene, which is inherited in an autosomal recessive manner.

Market Dynamics

Market players are engaged in receiving approvals from regulatory authorities, which is one of the important steps for launching products in the market. This is expected to drive growth of the global Niemann-Pick disease type C treatment market over the forecast period. For instance, on September 16, 2020, Orphazyme A/S, a biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval, with priority review for New Drug Application (NDA), for arimoclomol for the treatment of NPC.

Market players are involved in conducting research and development in order to identify targets for the disease, against which a new treatment can be developed in the future. For instance, in 2018, Centogene AG Rostock, a genetic diagnostic company, initiated a clinical trial to prepare a cell culture from patients suffering from Niemann Pick disease type C for the identification of novel proteins involved in pathways that leads to disease progression. This will also aid in early diagnosis. The proteins can be targeted for the development of treatment options for NPC, which is expected to drive growth of the market.

Key features of the study:

  • This report provides an in-depth analysis of global Niemann-Pick disease type C treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020 - 2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global Niemann-Pick disease type C treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Orphazyme ApS, CTD Holdings Inc, Neurotrope Inc, Okklo Life Sciences Bv, Intrabio Ltd, Azafaros, Centogene AG Rostock, Actelion Pharmaceuticals Ltd, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Alexion Pharmaceuticals, Sanofi Genzyme, and Aldagen Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global Niemann-Pick disease type C treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the Niemann-Pick disease type C treatment market

Detailed Segmentation:

  • Global Niemann-Pick Disease Type C Treatment Market, By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • Global Niemann-Pick Disease Type C Treatment Market, By Age Group:
    • Infantile
    • Juvenile
    • Adult
  • Global Ophthalmic Refractometer Market, By Region:
    • North America
  • By Country
    • U.S.
    • Canada
  • By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • By Age Group
    • Infantile
    • Juvenile
    • Adult
    • Europe
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • By Age Group
    • Infantile
    • Juvenile
    • Adult
    • Asia Pacific
  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • By Age Group
    • Infantile
    • Juvenile
    • Adult
    • Latin America
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • By Age Group
    • Infantile
    • Juvenile
    • Adult
    • Middle East
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • By Age Group
    • Infantile
    • Juvenile
    • Adult
    • Africa
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • By Disease Type:
    • Niemann-Pick disease type C1
    • Niemann-Pick disease type C2
  • By Age Group
    • Infantile
    • Juvenile
    • Adult
  • Company Profiles
  • Orphazyme ApS*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • CTD Holdings Inc
  • Neurotrope Inc
  • Okklo Life Sciences Bv
  • ntrabio Ltd
  • Azafaros
  • Centogene AG Rostock
  • Actelion Pharmaceuticals Ltd
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Alexion Pharmaceuticals
  • Sanofi Genzyme
  • Aldagen Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Age Group
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Key Developments
  • Market Trends
  • Merger and Acquisitions Scenario
  • New Product Approvals/Launch
  • PEST Analysis

4. Niemann-Pick Disease Type C Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

  • COVID - 19 Epidemiology
  • Impact of COVID-19 on Clinical trials
  • Government initiatives to combat COVID-19

5. Global Niemann-Pick Disease Type C Treatment Market, By Disease Type, 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Niemann-Pick Disease Type C1
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Niemann-Pick Disease Type C2
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Niemann-Pick Disease Type C Treatment Market, By Age Group, 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Infantile
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Juvenile
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Niemann-Pick Disease Type C Treatment Market, By Region, 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Disease Type, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Age Group, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Disease Type, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Age Group, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Disease Type, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Age Group, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Disease Type, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Age Group, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Disease Type, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Age Group, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Disease Type, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Age Group, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Orphazyme ApS
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • CTD Holdings Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Neurotrope Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Okklo Life Sciences B.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Intrabio Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Azafaros
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Centogene AG Rostock
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Actelion Pharmaceuticals Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Mallinckrodt Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Merck & Co., Inc.,
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Alexion Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Sanofi Genzyme
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Aldagen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact